RxDoctor Payments Data

Christopher Barone, NP

Family · Niagara Falls, NYNPI 1114470390

Payments from drug & device makers

$620in general payments, 2019–2025

Across 15 payments — averaging $41.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$167
  • Ardelyx, Inc.$150
  • Amgen$130
  • Indivior Inc.$70
  • Travere Therapeutics, Inc.$53
  • AstraZeneca$20
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$620 in reported general payments places this provider in the 60th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$2,229
Medicare patients
11
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate166$32,627
ProsolParenteral Amino Acid 20% No.1166$28,390
VivitrolNaltrexone Microspheres16$26,067
ClinisolParenteral Amino Acid 15% No.5106$19,979
LokelmaSodium Zirconium Cyclosilicate26$19,894
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$6,403
Calcium Acetate61$3,932
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl30$3,468
Bumetanide39$1,265
Nifedipine ErNifedipine18$855
Lidocaine-PrilocaineLidocaine/Prilocaine19$578
Gabapentin49$535
Ondansetron Hcl18$408
Metoprolol Succinate23$316
Torsemide20$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Vivitrol$16$26,06716 claims
AstraZenecaLokelma$20$19,89426 claims
Indivior Inc.Suboxone$70$6,40314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,883 family providers in New York.

Other family in Niagara Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →